hrp0097p1-104 | GH and IGFs | ESPE2023

Healthcare professionals’ perceptions on the quality and evolution of digital health devices to support paediatric growth hormone therapy: Results of a French participatory study

Rivera-Romero Octavio , Perge Kevin , Cochet Solenn , Trouvin Marie-Agathe , Koledova Ekaterina

Background: Treatment of growth hormone deficiency (GHD) requires daily injections over many years. Connected digital health devices can facilitate GH treatment by automating the injection process, which reduces anxiety, and collecting injection data in real-time so that accurate adherence information is available to healthcare professionals (HCPs). In developing new digital health solutions, HCP perspectives should be considered.<strong...

hrp0097fc6.3 | Pituitary, neuroendocrinology and puberty 1 | ESPE2023

Is the 24-hour urinary gonadotropin assay an effective diagnostic tool in central precocious puberty? A retrospective study of threshold setting and validation in two cohorts.

Janot Clément , Perrin Pauline , Bretones Patricia , Malburet-Testori Sarah , Perge Kevin , Raverot Véronique , Robert Zoé , Roucher-Boulez Florence , Villanueva Carine , Nicolino Marc , Plotton Ingrid

Background and Aims: Central Precocious Puberty (CPP) caused by the early activation of the hypothalamic-pituitary-gonadal axis is a rare affection that occurs in 0.2% in girls. Clinical signs are suggestive and LHRH-test could be sometimes difficult to use and not always contributive. Gonadotropin assay in twenty-four hours-urinary collection could be an interesting option. The present work intended to evaluate the diagnostic interest of 24-hour urinary gonad...